William Blair Reiterates an 'Outperform' on Dynavax (DVAX); Heplisav VRBPAC Panel Set - What to Watch For

August 29, 2012 10:09 AM EDT Send to a Friend
Get Alerts DVAX Hot Sheet
Price: $1.62 +5.88%

Rating Summary:
    6 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade DVAX Now!
Join SI Premium – FREE
William Blair reiterates an 'Outperform' on Dynavax Technologies (NASDAQ: DVAX) price target of $9.00.

Analyst, Y. Katherine Xu, said, "A favorable vote could lead to potential approval and launch in the United States in first quarter 2013. We continue to assign 90% probability to eventual approval and a full adult label (18-70 years as opposed to 40-70 years). We note that Dynavax submitted Heplisav’s biological license application (BLA) in April, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults aged 18 through 70."

We summarize the key issues to watch for in the VRBPAC panel review as follows: 1) Efficacy should be unequivocal; 2) Safety will be the focus of discussion, in our opinion; and 3) Discussions might also focus on the one case of Wegener’s granulomatosis that put Heplisav on clinical hold during 2008-2009.

For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.

Shares of Dynavax Technologies closed at $3.83 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA

Related Entities

William Blair

Add Your Comment